Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 7/20 | 0.59 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.53 |
| ▸ | CSNK1D | P48730 | 8/20 | 0.44 |
| ▸ | CSNK1E | P49674 | 8/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17767692 | 0.92 | TGFBR1 (0.52) | TGFBR1TGFBR2CSNK1DCSNK1EPDE10A | |
| SCHEMBL17767676 | 0.89 | TGFBR1 (0.49) | TGFBR1TGFBR2CSNK1DCSNK1EPDE10A | |
| SCHEMBL17767543 | 0.89 | TGFBR1 (0.52) | TGFBR1TGFBR2CSNK1DCSNK1EPDE10A | |
| SCHEMBL17767752 | 0.88 | TGFBR1 (0.48) | TGFBR1TGFBR2CSNK1DCSNK1EPDE10A | |
| SCHEMBL17767586 | 0.88 | TGFBR1 (0.51) | TGFBR1TGFBR2CSNK1DCSNK1EFLT3 | |
| SCHEMBL17767422 | 0.87 | TGFBR1 (0.47) | TGFBR1TGFBR2CSNK1DCSNK1EPDE10A | |
| SCHEMBL17767551 | 0.86 | TGFBR1 (0.49) | TGFBR1TGFBR2CSNK1DCSNK1EPDE10A | |
| SCHEMBL17767596 | 0.86 | TGFBR1 (0.49) | TGFBR1TGFBR2CSNK1DCSNK1EPDE10A | |
| SCHEMBL17767532 | 0.85 | TGFBR1 (0.48) | TGFBR1TGFBR2CSNK1DCSNK1EPDE10A | |
| SCHEMBL17767590 | 0.85 | TGFBR1 (0.46) | TGFBR1TGFBR2CSNK1DCSNK1EPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696693-B2 | Fused imidazole derivatives as TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-30 | — | — | US | claimed |
| US-20180346487-A1 | Fused Imidazole Derivatives as TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2018-12-06 | — | — | US | claimed |
| EP-3221318-A1 | FUSED IMIDAZOLE DERIVATIVES AS TGF-BETA INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2017-09-27 | — | — | EP | claimed |
| WO-2016081364-A1 | FUSED IMIDAZOLE DERIVATIVES AS TGF-BETA INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-26 | — | — | WO | claimed |
| US-10696693-B2 | Fused imidazole derivatives as TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10696693-B2 | Fused imidazole derivatives as TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20180346487-A1 | Fused Imidazole Derivatives as TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2018-12-06 | — | — | US | disclosed |
| EP-3221318-A1 | FUSED IMIDAZOLE DERIVATIVES AS TGF-BETA INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016081364-A1 | FUSED IMIDAZOLE DERIVATIVES AS TGF-BETA INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016081364-A1 | FUSED IMIDAZOLE DERIVATIVES AS TGF-BETA INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696693-B2 | Fused imidazole derivatives as TGF-beta inhibitors | TGFBR1, TGFBR2, SMAD3 | TGFBR1 1/4885TGFBR2 2/4885CSNK1D 417/4885 |
| US-20180346487-A1 | Fused Imidazole Derivatives as TGF-Beta Inhibitors | TGFBR1, TGFBR2, SMAD3 | TGFBR1 1/4885TGFBR2 2/4885CSNK1D 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.